High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML

Blood

Volumn 101, Issue 6, 2003, Pages 2152-2155

  Lange, Thoralf ^b   Günther, Christine ^b   Köhler, Thomas ^b   Krahl, Rainer ^b   Musiol, Scarlet ^b   Leiblein, Sabine ^b   Al Ali, Haifa Kathrin ^b   Van Hoomissen, Iris ^b   Niederwieser, Dietger ^b   Deininger, Michael W N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX;

ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; BLAST CELL CRISIS; CANCER REGRESSION; CANCER RESISTANCE; CANCER RISK; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT;

EID: 0345144023     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1366     Document Type: Article

References (12)

1. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 2002;99:2304-2309.
2. Sacchi S, Kantarjian HM, O'Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632-2641.
3. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
4. Visani G, Rosti G, Bandini G, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol. 2000;109:722728.
5. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeioid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
6. Kohler T, Schill C, Deininger MW, et al. High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML). Leukemia. 2002;16:22-29.
7. Wurl P, Kappler M, Meye A, et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet. 2002;359:943-945.
8. Deininger M, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90:3691-3698.
9. Ravandi F, Kantarjian HM, Talpaz M, et al. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer. 2001;91:1964-1972.
10. Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol. 2002;116:834-838.
11. Deininger MWN, Schäfer K, O'Brien S, et al. STI571 prior to allogeneic stem cell transplantation (SCT): a retrospective analysis by the European blood and marrow transplantation group (EBMT) and the international STI571 investigators [abstract]. Hematol J. 2001;1:96.
12. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96:3195-3199.